Aroa Biosurgery (ARX) Aandelenoverzicht
Aroa Biosurgery Limited ontwikkelt, produceert en verkoopt medische hulpmiddelen voor het herstel van wonden en weke delen met behulp van extracellulaire matrix (ECM)-technologie in de Verenigde Staten en daarbuiten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 4/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
ARX Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aroa Biosurgery Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | AU$0.56 |
| 52 Week Hoogtepunt | AU$0.80 |
| 52 Week Laag | AU$0.49 |
| Bèta | 0.85 |
| 1 maand verandering | -6.61% |
| 3 maanden verandering | 10.78% |
| 1 Jaar Verandering | -4.24% |
| 3 jaar verandering | -39.89% |
| 5 jaar verandering | -52.32% |
| Verandering sinds IPO | -58.15% |
Recent nieuws en updates
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.Recent updates
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Rendement voor aandeelhouders
| ARX | AU Biotechs | AU Markt | |
|---|---|---|---|
| 7D | -5.8% | -3.7% | -0.3% |
| 1Y | -4.2% | -51.6% | 0.05% |
Rendement versus industrie: ARX overtrof de Australian Biotechs industrie, die het afgelopen jaar een rendement -51.6 % opleverde.
Rendement versus markt: ARX presteerde slechter dan Australian Market, dat het afgelopen jaar een rendement van 0.1 % opleverde.
Prijsvolatiliteit
| ARX volatility | |
|---|---|
| ARX Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 16.6% |
| 10% least volatile stocks in AU Market | 3.8% |
Stabiele aandelenkoers: ARX heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Australian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 8% ) van ARX is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Brian Ward | aroa.com |
Aroa Biosurgery Limited ontwikkelt, produceert en verkoopt medische hulpmiddelen voor het herstel van wonden en weke delen met behulp van extracellulaire matrix (ECM)-technologie in de Verenigde Staten en daarbuiten. De producten omvatten Endoform Natural en Endoform Antimicrobial Restorative Bioscaffold voor de behandeling van acute en chronische wonden; Myriad Matrix, een geconstrueerde ECM voor het herstel van weke delen, versterking en complexe wonden; Myriad Morcells, een gemorceliseerd (poedervormig) formaat van Myriad Matrix voor het herstel van weke delen en complexe wonden; Myriad Morcells Fine, dat een bolus van biologisch belangrijke ECM-eiwitten levert om de genezing op gang te helpen en te ondersteunen; en Symphony, een combinatieproduct van cellen en weefsels, geïndiceerd voor de regeneratie van functioneel weefsel in complexe wonden. Het bedrijf ontwikkelt ook producten voor buikwandreconstructie, herniaherstel en borstreconstructie in Noord-Amerika en Europa.
Aroa Biosurgery Limited Samenvatting
| ARX fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | AU$195.43m |
| Inkomsten(TTM) | AU$3.89m |
| Inkomsten(TTM) | AU$86.41m |
Is ARX overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ARX resultatenrekening (TTM) | |
|---|---|
| Inkomsten | NZ$103.85m |
| Kosten van inkomsten | NZ$15.03m |
| Brutowinst | NZ$88.83m |
| Overige uitgaven | NZ$84.15m |
| Inkomsten | NZ$4.68m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 0.014 |
| Brutomarge | 85.53% |
| Nettowinstmarge | 4.50% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde ARX op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/22 05:13 |
| Aandelenkoers aan het einde van de dag | 2026/07/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Aroa Biosurgery Limited wordt gevolgd door 4 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |